Zobrazeno 1 - 10
of 13
pro vyhledávání: '"B J, Kinon"'
Autor:
J. P. Houston, S. C. Kirkwood, D. J. Fu, D. H. Adams, M. Farmen, A. C. M. Downing, N. Mukhopadhyay, A. Breier, B. J. Kinon, H. Liu-Seifert, J. Houston, C. Kaiser, J. Ahl, F. M. Braga, V. Aroniadou-Anderjaska, H. Li, M. A. Rogawski, J. Wernicke, Y. Lu, J. Hall, D. DeSouza, A. Waninger, P. Tran, A. Rosen, T. Lee, S. Iyengar, K. Knopp, D. Goldstein, S. Ahmed, R. Entsuah, W. Ortega-Leon, M. Eng, R. Tummala, I. Lipkovich, W. Deberdt, P. Buckley, J. Csernansky, J. Peuskens, S. Kollack-Walker, M. Rotelli, S. Giovanni, F. Amhed, V. Movsesyan, I. Cernak, S. Schinelli, B. Stoica, A. Faden, K. R. Byrnes, J. Garay, S. Fricke, A. I. Faden, J. P. Bennett, J. Sridhar, N. Akula, H. Abaan, A. Uren, Y. Tomita, L. Zoubak, N. Pattabiraman, A. Ekwerike, T. Nakajima, H. Kamei, H. Kawakami, T. Hayashi, H. Saeki, J. French, D. Briggs, C. Lee, K. Spiegel, R. N. Williams, T. N. Chase
Publikováno v:
NeuroRX. 2:533-538
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fdb62c4d1be657b78ac2b70079ae4756
https://doi.org/10.1602/neurorx.2.3.533
https://doi.org/10.1602/neurorx.2.3.533
Autor:
J S, Kennedy, F P, Bymaster, L, Schuh, D O, Calligaro, G, Nomikos, C C, Felder, M, Bernauer, B J, Kinon, R W, Baker, D, Hay, H J, Roth, M, Dossenbach, C, Kaiser, C M, Beasley, J H, Holcombe, M B, Effron, A, Breier
Publikováno v:
International journal of geriatric psychiatry. 16
Olanzapine (OLZ) is unique among currently available antipsychotic medications in its antagonism of a range of receptor systems including dopamine, norepinephrine, serotonin, acetylcholine, and histamine. Olanzapine's mechanistic complexity provides
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::804501eee12f73d97564694a6a147ff1
https://pubmed.ncbi.nlm.nih.gov/11748788
https://pubmed.ncbi.nlm.nih.gov/11748788
Publikováno v:
The Journal of clinical psychiatry. 62(2)
Weight change and the weight-related health factors of nonfasting serum glucose, serum cholesterol, and diastolic blood pressure levels were analyzed in patients with DSM-III-R schizophrenia and related disorders who received treatment with olanzapin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::51cfc112225d236538ab275b4e19e038
https://pubmed.ncbi.nlm.nih.gov/11247108
https://pubmed.ncbi.nlm.nih.gov/11247108
Publikováno v:
The Journal of clinical psychiatry. 62
Behavioral agitation and prominent positive psychotic symptoms often characterize the acute presentation of schizophrenia. The clinical treatment goal is a rapid control of these symptoms. The relative efficacy of olanzapine, a novel antipsychotic dr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::421755a4518c04bb97e4a8cd33134763
https://pubmed.ncbi.nlm.nih.gov/11232746
https://pubmed.ncbi.nlm.nih.gov/11232746
Publikováno v:
The Journal of clinical psychiatry. 62
Schizophrenic patients who have been prescribed atypical antipsychotics have a potential risk of gaining weight. The implications of weight gain for clinical care may differ depending on whether a patient is underweight or overweight at baseline. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ae885f9509549201d02ae9200c05bd78
https://pubmed.ncbi.nlm.nih.gov/11232752
https://pubmed.ncbi.nlm.nih.gov/11232752
Publikováno v:
Journal of clinical psychopharmacology. 19(5)
The abrupt appearance of clozapine discontinuation symptoms represents a particularly unique situation that has not been characterized in a double-blind, placebo-controlled trial. A randomized, double-blind comparison of placebo (N = 53) and olanzapi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ff82ad3e3102c936b2f4378d5a82365b
https://pubmed.ncbi.nlm.nih.gov/10505585
https://pubmed.ncbi.nlm.nih.gov/10505585
Autor:
B J, Kinon
Publikováno v:
The Journal of clinical psychiatry. 59
Placebo-controlled maintenance studies of conventional antipsychotic agents demonstrate a significant reduction in the risk of schizophrenic relapse in neuroleptic-treated patients. Neuroleptic discontinuation even in patients who remained in remissi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::818d6066e741aa013e99524e034e0a7b
https://pubmed.ncbi.nlm.nih.gov/9847048
https://pubmed.ncbi.nlm.nih.gov/9847048
Autor:
B. J. Kinon, Jeffrey A. Lieberman
Publikováno v:
Psychopharmacology. 124(1-2)
Various criteria used to define atypical antipsychotic drugs include: 1) decrease, or absence, of the capacity to cause acute extrapyramidal motor side effects (acute EPSE) and tardive dyskinesia (TD); 2) increased therapeutic efficacy reflected by i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9a8d5ff73377c55a16946a002db294f
https://pubmed.ncbi.nlm.nih.gov/8935797
https://pubmed.ncbi.nlm.nih.gov/8935797
Publikováno v:
Psychopharmacology bulletin. 31(3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c985ed710dcc3a3f8cc5382108826b88
https://pubmed.ncbi.nlm.nih.gov/8668750
https://pubmed.ncbi.nlm.nih.gov/8668750
Publikováno v:
Psychopharmacology bulletin. 29(3)
The relative efficacy of conventional treatment alternatives that are routinely used to treat acutely relapsed schizophrenic patients who have failed an initial course of standard neuroleptic therapy has not been adequately studied, nor have predicto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fdb6b7b54704bdf0c58dca4cf55a62c6
https://pubmed.ncbi.nlm.nih.gov/7907184
https://pubmed.ncbi.nlm.nih.gov/7907184